Activation of the Hedgehog pathway may have therapeutic value for improved bone healing, taste receptor cell regeneration, and alleviation of colitis or other conditions. Systemic pathway activation, however, may be detrimental and therapeutic application has been difficult for lack of agents amenable to tissue targeting. We have developed a novel agonist, a conformation-specific nanobody against the Hedgehog receptor Patched1. This nanobody potently activates the Hedgehog pathway in vitro and in vivo by stabilizing an alternative conformation of a Patched1 "switch helix", as revealed by cryo-EM structure determination. Although this conformation likely constitutes part of the transport cycle, nanobody-trapping disrupts the cycle and prevents substrate movement through the Patched1 sterol conduit. Our conformation-selective nanobody approach provides a new route to the development of transporter-related pharmacologic agents and may be generally applicable to the study of other transporters.
organs, such as bladder carcinoma, and colon and pancreatic adenocarcinoma 4-9. Pathway activation may also confer therapeutic benefits in regeneration of taste receptor cells of the tongue 10, which are often lost or diminished in chemotherapy patients, in protection or recovery from diseases such as colitis 9, reduction of tissue overgrowth in prostatic hypertrophy 11, or acceleration of bone healing in diabetes 12. Despite the potential benefits of pathway activation and the availability of potent small molecule pathway activators 13, however, systemic pathway-activating therapies have not been pursued clinically, in part because such treatments are likely to cause overgrowth of mesenchyme and potential initiation or exacerbation of fibrosis in many organs 6,14. These dangerous side effects might be avoided by restricting pathway activation to specific organs or tissue compartments. Restricted pathway activation could be accomplished through conjugation of a pathway agonist to another agent, such as an antibody, that targets specific tissues or organs. Such targeting would be most easily accomplished with a synthetic or genetically encoded peptide as the agonist. Use of the Hedgehog protein for this purpose, however, is hampered by the requirement of lipid modifications for its activity 15,16; these modifications include a cholesteryl moiety on its carboxy-terminus, acquired during auto-processing of the Hedgehog precursor 17, and a palmitoyl adduct on its amino-terminus, catalyzed by the acyltransferase Ski1/HHAT 18. Other synthetic or genetically-encoded peptides that could easily be conjugated to targeting agents are currently lacking.
Recent insights into the mechanism of Hedgehog signal transduction suggest a route to remedying this deficiency. The primary receptor for Hedgehog is Patched1 (PTCH1), which maintains pathway quiescence by suppressing Smoothened (SMO) a downstream G-protein coupled receptor (GPCR)-like protein 19-21. When bound to Hedgehog PTCH1 is inactivated, permitting SMO to become active and trigger downstream signaling events 21-24. Mechanistically, the activation of SMO requires binding of a sterol, likely entering the 7TM bundle from the inner leaflet of the plasma membrane 25-30. PTCH1 is proposed to prevent SMO activation by transporting sterols from the inner leaflet of the plasma membrane, thereby limiting SMO access to activating sterols 31-34. A hydrophobic conduit coursing through the PTCH1 extracellular domain is required for this transport activity 33, and Hedgehog blocks this conduit and inactivates PTCH1 by inserting its essential amino-terminal palmitoyl adduct 32-35. Transporters typically act by moving through a repeated cycle of conformational changes. If PTCH1 transport function employs such a conformational cycle, an agent that preferentially binds and stabilizes a specific PTCH1 conformation would be expected to disrupt its conformational cycle and transport activity, thus permitting activation of SMO. Such an agent thus may serve as a pathway modulator that could make lipid modifications dispensable and may shed light on conformational changes that occur during the PTCH1 working cycle.
Development of a conformation-specific pathway activating agent
Nanobodies are single-chain antibody fragments 36 that have frequently been used to stabilize specific GPCR protein conformations 37, and are amenable to genetic engineering. We have chosen as a starting point a synthetic yeast display library to select for conformation-specific nanobodies against PTCH1 38. To select conformationspecific nanobodies we first introduced conformational bias in PTCH1 by altering three acidic residues buried within its transmembrane domain (termed PTCH1-NNQ). These acidic residues, conserved within the RND transporter family, are required for PTCH1 activity in sterol transport and SMO regulation 26, 33 and are more generally proposed to drive conformational changes in RND transporters in response to cation influx (Fig. 1a ).
We thus reasoned that alteration of these residues in PTCH1 might affect the relative representation of its conformational states.
We used purified PTCH1-NNQ variant protein for selection of nanobody clones from the yeast display library. After several rounds of enrichment for PTCH1-NNQ binding yeast clones, we selected nanobodies that preferentially bind to PTCH1-NNQ versus wild-type PTCH1, using FACS (Fluorescence Activated Cell Sorting) and wildtype and NNQ PTCH1 proteins labeled with antibodies coupled to different fluorophores ( Fig. 1b ). Yeast cells expressing preferentially-bound nanobodies form a population off the diagonal of the FACS plot ( Fig. 1c ). After selecting nanobody-expressing yeast cells in the NNQ-preferring population, 15 unique clones were identified from sequencing, of which three were discarded because they bind directly to the antibody used during selection (Extended Data Fig. 1a, b ). As PTCH1 and PTCH1-NNQ differ only in the acidic residues in the transmembrane domain, differences in nanobody binding most likely derive from differences in conformational states between PTCH1 and PTCH1-
NNQ.
Stabilization of a specific PTCH1 conformation would be expected to inactivate its transport activity and permit downstream response in the Hedgehog pathway. We therefore tested the activity of purified nanobody proteins on 3T3-Light2 cells, using a Gli-dependent luciferase assay. Clones 17, 20, and 23 showed weak activation effects ( Fig. 1d ). We enhanced signaling potency through two rounds of affinity maturation, first by selection from an error-prone PCR library (Extended Data Fig. 1c, d) , and then from a library targeting the complementarity-determining regions (CDRs) using one-pot mutagenesis 39(Extended Data Fig. 1e , f). The first round of affinity maturation yielded a series of nanobody clones deriving from clone 23, with H105R, G106R substitutions in CDR3 and several variant residues at G50 in CDR2. Only one of these variants, the G50T substitution (named "T23"), could be expressed for purification from E. coli. T23 showed enhanced potency in Gli-dependent luciferase assays (Fig. 1e ), and was used as the starting sequence for a second round of affinity maturation, in which all CDR residues were systematically randomized in one-pot mutagenesis. After selection based on PTCH1 binding, Y102I in CDR3 was enriched, as well as T77N, an unintended substitution. The purified TI23 nanobody also exhibited greater potency in pathway activation than its T23 parent ( Fig. 1e ). All of the nanobody variants showed preferential binding for PTCH1-NNQ, as revealed by two-color staining of yeast cells expressing these variants ( Fig. 1f ; Extended Data Fig. 1g ). TI23 also strongly activated human Hedgehog pathway targets GLI1 and PTCH1 at low nanomolar concentrations when tested in a cell line derived from human embryonic palatal mesenchymal (HEPM) 40(Fig. 1g).
In vivo activation of the Hedgehog pathway
As a small protein (~12kDa), a nanobody might be expected to display excellent tissue penetrance and be readily accessible to cells in most tissues. We tested the activity of TI23 by intravenously injecting mice with adeno-associated virus (AAV) engineered to express it. This experiment should permit observation of biological effects elicited by sustained nanobody exposure as AAV infection is maintained over several weeks. We monitored lingual epithelium and skin, as these tissues display well-characterized responses to Hedgehog pathway activation 10,41. We examined Gli1 mRNA by fluorescence in situ hybridization (FISH) as an indicator of pathway activation in lingual epithelium, and noted marked expansion of the range of Gli1 expression in ShhN or TI23-virus injected mice as compared to the animals that received the control virus ( Fig. 2a ). A similar expansion of Gli1 expression was also noted in mice given SAG21k ( Fig. 2a ), a small molecule Hedgehog agonist that activates SMO 13. The TI23 nanobody also augmented Hedgehog pathway activity in the dorsal skin, as indicated by a 6-fold increase in Gli1 RNA levels ( Fig. 2B ). We also noted lengthening hair in the hair follicle and expansion of dermal adipocytes upon histological examination of dorsal skin in mice infected with AAV encoding TI23 or ShhN, but not control nanobody, indicating hair follicle entry into the anagen phase of the hair cycle ( Fig. 2c ). Consistent with accelerated entry into anagen, we noted faster hair regrowth on the dorsal skin after shaving ( Fig. 2d ).
Structure of the PTCH1::TI23 complex
To determine the conformational effects of TI23 binding to PTCH1 we prepared the PTCH1::TI23 complex for structure determination by cryo-EM. The complex was clearly visualized in cryo-EM micrographs (Extended Data Fig. 2a ), with well-fitted contrast transfer function parameters (CTF; Extended Data Fig. 2b ) and 2D class averages (Extended Data Fig. 2c ). 3D reconstruction of a cryo-EM dataset yielded a high quality map ( Fig. 3a ; procedure in Extended Data Fig. 2d ) at a resolution of 3.4 Å (Extended Data Fig. 2f ; Table 1 ). All 12 transmembrane (TM) helices and two major extracellular domains (ECDs) were resolved (Fig. 3a) , and an atomic model of the PTCH1::TI23 complex was built based on this map and the previously determined murine PTCH1 structure 33. Most of the intracellular sequence was unresolved, and not modeled, except for two transverse helices preceding TM1 and TM7 (Fig. 3b ).
Sterol-like densities were identified in multiple sites, one in a pocket at the distal tip of ECD1 (farthest from the membrane, density I), one in the cavity proposed as part of the transport conduit (II) and two more at the periphery of the transmembrane domain (III and IV) ( Fig. 3b ). The density in site II is especially well resolved, and its unusual "Y" shape strongly suggests that it is glyco-diosgenin (GDN), the detergent used during sample preparation (Extended Data Fig. 3b ). The other sterol-like densities are also most likely GDN, but only the steroidal moiety of GDN, digitogenin, was resolved and modeled.
The nanobody interacts only with ECD1 of PTCH1, as shown in the schematic drawing ( Fig. 3c ). The binding site of TI23 overlaps with that of SHH, which interacts with both ECD1 and ECD2. CDR1 and CDR3 loops from TI23 sandwich a short helix in PTCH1 ECD1, which we name as the "switch helix". CDR1 primarily interacts with PTCH1 by inserting hydrophobic residues I28 and F29 into the hydrophobic pocket at lipid site I, whereas CDR3 primarily forms a hydrogen bond network with other residues on the surface of PTCH1 ( Fig. 3d ).
Although TI23 interacts exclusively with ECD1, we noted significant improvement in the resolution of side chains within the transmembrane domain. Of particular interest, the charged residue triad within the transmembrane (TM) domain that was altered for selection of TI23 is clearly visible as compared to other published PTCH1 structures, none of which have well resolved side chain density for these residues. This apparent stabilization of transmembrane residues suggests potential communication of the transmembrane domain with the ECD. Such allostery would account for the improvement of the TM resolution upon TI23 binding to wild-type PTCH1, while also explaining preferential binding of TI23 to PTCH1-NNQ during selection ( Fig. 1c ). Our model further suggests that these acidic residues may be stabilized by side chain interaction with residues nearby, namely, N541 in TM5 and H1085 in TM10 ( Fig. 3e ).
Indeed, alanine substitution of these residues impaired PTCH1 activity ( Fig. 3f ) without affecting the overall fold, as indicated by preserved binding to ShhN (Fig. 3g ).
The overall structure of the PTCH1::TI23 complex is similar to the unbound murine PTCH1 structure, with a root mean square deviation of 0.955 Å of the Cα carbon atoms over 910 residues. Both ECD1 and ECD2 display some conformational differences in the complex. One minor difference is a rotation of ECD2 around its connection to the TM domain by ~5 degrees towards ECD1 as compared to PTCH1 alone ( Fig. 4a ). A more marked difference is the rotation by ~32 degrees of the distal tip of a short helix within ECD1 towards the membrane, in a manner suggestive of a flipped switch ( Fig. 4a , inset). We term this helix the "switch helix" (residues 203-209, highlighted in Fig. 3c ), and refer to its conformations in PTCH1 alone and in the PTCH1::TI23 complex as poses 1 and 2, respectively. These two alternative poses of the switch helix are present but have gone unremarked in other structures of PTCH1 determined under various conditions. For example, in the ternary complex of a single native Shh ligand bound to two human PTCH1 molecules 32, PTCH1 from chain a, the molecule whose sterol conduit is occluded by interaction with the N-terminal palmitoyl moiety of the SHH ligand, adopts pose 2, whereas PTCH1 from chain b adopts pose 1 32 . Indeed, in all published structures of PTCH1 the switch helix adopts one or the other of these two poses15, [31] [32] [33] [34] [35] 42 , suggesting that they represent discrete alternative conformations preferentially populated within the PTCH1 activity cycle ( Fig. 4b ).
Effects of the switch helix on the sterol conduit
These structural rearrangements alter the shape of the transport conduit as assessed by the Caver program (Fig. 5a ). The region of the conduit encompassing sterol I in murine PTCH1 thus is seen to be dramatically constricted in the conduit of the PTCH1::TI23 complex, and the conduit in the PTCH1::TI23 complex also acquires a distal opening to the exterior (Fig. 5b ). In parallel with this change in conduit shape, the bound sterol-like density shifts from a more proximal enclosed cavity to a more distal position with an opening to the exterior (Fig. 5c ). This concerted proximal constriction and distal expansion results primarily from rotation of the switch helix. If PTCH1 activity is, like other RND family members, driven by a chemiosmotic gradient26, the conformational change identified here may form part of a defined sequence that results in directional movement of substrates within the transport conduit.
The best-studied bacterial RND homolog, AcrB, also undergoes a series of conformational transitions that affect the substrate conduit, similar in principle although distinct in detail from that of PTCH1. As the AcrB transporter moves between conformations, the substrate conduit changes shape to admit substrate proximally and move it to the central portion of the conduit (L and T states), then to open distally while constricting proximally (O state), thus expelling substrate from the distal tip of the ECD 43. The TI23 nanobody appears to stabilize pose 2 of the PTCH1 switch helix. If PTCH1-mediated transport of sterols away from the inner leaflet indeed depends on the dynamic changes in the shape of the conduit associated with switch helix movement, TI23 binding may lock PTCH1 in a state that is incompatible with sterol movement. To test this idea, we utilized a solvatochromic fluorescent sterol sensor, microinjected into cells to permit ratiometric measurement of sterol available for binding within the inner leaflet of the membrane 44. This sensor previously revealed that available sterol decreases sharply with PTCH1 activity, and that PTCH1 inactivation by Shh ligand causes a return to normal sterol availability 33. Similar to the effect of Shh ligand addition, we noted that TI23 addition reversed the PTCH1-mediated reduction in cholesterol activity ( Fig. 5d ).
Discussion
The therapeutic applications of Hedgehog pathway modulation have focused primarily on pathway antagonists, and inhibition of the Hedgehog pathway has proven efficacious in the treatment of cancers driven by excessive Hedgehog pathway activity directly in primary cells of the tumor 1,2. In other cancers, however, Hedgehog pathway blockade may accelerate tumor growth and progression. These include pancreatic, colon, and bladder cancers, and likely other malignancies originating from organs of endodermal origin, in which Hedgehog pathway activity in stromal cells may restrain cancer progression. Other therapeutic applications for pathway activation may include regeneration of taste receptor cells in chemotherapy-treated patients 10 or regeneration of bone in diabetic patients 12. Current candidates as pharmaceutical agents that activate the Hedgehog pathway are all hydrophobic in nature, including small molecule members of the SAG family 45, certain oxysterols 46,47, and purmorphamine 48, all of which target SMO, and the lipid-modified Hedgehog protein or its derivatives, which target PTCH1. Our conformation-selective PTCH1-directed nanobody TI23 represents a new class of potent, more hydrophilic agonists, which unlike the native Hedgehog protein does not require hydrophobic modification for activity. TI23 furthermore has the potential to be engineered for targeting by fusion to an antibody or other agent with tissue or cell-type specificity. This potential for greater specificity is critical for translational applications, as Hedgehog responsive cells are widespread and systemic pathway activation may have pleiotropic effects and cause complications such as fibrosis.
TI23 is not only a promising candidate for further pharmaceutical development, but also provides insight into the PTCH1 transport mechanism. Directional movement of substrate through a transporter protein implies conformational change, but the identification of such conformational transitions for transporters is a nontrivial challenge.
Our conformation-specific nanobody approach allowed us to identify two distinct conformations associated with poses 1 and 2 of the PTCH1 switch helix. The changes in shape of the transport conduit associated with these poses suggest a potential mechanism for directed substrate movement. As PTCH1 is distinct from the wellcharacterized RND transporter AcrB in both its preferred substrate and its extracellular domain structure49, it is not surprising that the conformational transitions of these proteins differ. Indeed, given these differences, the apparent similarity in peristaltic movement of the substrate conduit in both proteins seems quite remarkable.
Our conformation-selective nanobody approach may be generalizable to the study of other transporters, in particular other members of the RND family. In mammals this family includes the NPC1 cholesterol transport protein 50, and other PTCH-like proteins, such as PTCHD1, disruption of which is strongly associated with autism 51,52. For other transporters, mutations that disrupt function may do so by biasing the normal conformational landscape without uniquely stabilizing any one conformation. Selection of nanobodies that preferentially bind such mutants may enable capture of sparsely populated yet critical conformations, expanding the repertoire of experimentally accessible states for structural and functional studies. TM1  TM2  TM3  TM4  TM5  TM6  TM7  TM8  TM9  TM10  TM11  TM12   T I 2 This may reflect the difference in efficacy of these two ligands, as TI23 induces ~75% maximum pathway activity at saturating concentration in Gli-dependent luciferase assays. 
Materials and Methods

Cell culture
Yeast display selection
The synthetic nanobody library was grown in SDCAA media at 30 C to a cell density of 
Affinity maturation
The first round affinity maturation library was made with error-prone PCR. Nanobody Then cells expressing nanobody were incubated with Ptch1-C NNQ at 0.6 nM. After washing in selection buffer, the cells were incubated with the parental 17, 20, 23 nanobody proteins at 1 µM each for 170 min at room temperature. The cells were then stained with FITC-labeled HA antibody to mark nanobody expression levels and Alexa 647-labeled anti-1D4 antibody to mark PTCH1 binding. Cells that maintain high PTCH1 binding were selected from FACS. 64 clones were sequenced to identify repeating changes.
The second round of affinity maturation was performed with a library targeting the complementarity determining regions (CDRs) using the one-pot mutagenesis method . A pool of DNA oligos with NNK substituting each codon in the CDR regions was used for one-pot mutagenesis of the CDRs so that theoretically all 20 amino acids at each position were represented in this library. The DNA product from one-pot mutagenesis was then amplified with Q5 polymerase and purified with gel extraction. A final product ~5 µg DNA was used for yeast transformation. The transformed cells were grown in YPD media containing 100 µg/ml nourseothricin sulfate and induced in YPG media containing the same antibiotic. The cells were then incubated with 10 nM protein C-tagged Ptch1-C, washed in selection buffer and then incubated with 1µM 23T (purified nanobody protein with the consensus sequence from the 1 st round of affinity maturation) for one day. The cells were then stained with FITClabeled HA and Alexa 647 labeled anti-protein C antibody and the PTCH1-high cells were selected in FACS. The cells were grown in YPD and induced again. The same FACS selection procedure was repeated to further purify the population. The nanobody sequences from the plasmids prepared from the initial yeast library and the final selected library were then amplified with Q5 polymerase and sent for amplicon sequencing at MGH sequencing core.
PTCH1 purification
Purification of PTCH1 was performed as previously described with minor changes.
Suspension 293 cells were grown to a density of 1.2 -1.6 x 10 6 /ml, supplemented with 10 mM sodium butyrate, and infected with high-titer Ptch1-SBP baculoviruses for 40-48
hr. Cell pellets were stored at -80°C. Pellets were thawed into hypotonic buffer (20 mM HEPES pH 7.5, 10 mM MgCl 2 , 10 mM KCl, 0.25 M sucrose) supplemented with protease inhibitors and benzonase. Crude membranes were pelleted with centrifugation (100,000 x g, 30 min., 4°C). The pellet was resuspended in lysis buffer (300 mM NaCl, 20 mM HEPES pH 7.5, 2mg/ml iodoacetamide, 1% DDM / 0.2% CHS) with protease inhibitors and solubilized for 1 hour at 4°C with gentle rotation. After centrifugation (100,000 x g, 30 min., 4°C), the supernatant was incubated with streptavidin-agarose affinity resin in batch mode for 2-3 hours at 4°C with gentle rotation. The resin was packed into a disposable column, and washed with 20-30 column volumes of buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 0.03% DDM / 0.006% CHS). Protein was eluted in the same buffer supplemented with 2.5 mM biotin.
Cryo-EM data acquisition
Eluted Ptch1-B protein was mixed at 1:1.1 ratio with TI23 and then loaded onto Superdex 200 column pre-equilibrated with SEC buffer (20 mM HEPES, pH 8, 150 mM NaCl, 0.02% GDN). The peak fractions were collected and concentrated with an Amicon filter with molecular weight cutoff of 100 kDa to A280 ~4.5. 2.5 µL sample was applied to a glow-discharged quantifoil grid on a vitrobot. The sample chamber was kept at 100% relative humidity. The grid was blotted for 10s and plunged into liquid ethane bath cooled by liquid nitrogen.
The cryo grids were imaged on a Titan Krios 2 electron microscope operated at 300 kV.
Images were taken on the pre-GIF K2 camera in dose fractionation mode, at nominal maginification of 22.5k, corresponding to a pixel size of 1.059 Å (0.5295 Å per superresolution pixel). The dose rate was ~8e/pix/sec with a total exposure time was 12s at a frame rate of 0.2s/frame. Fully automated data collection was performed with SerialEM, with a defocus range of -1 µm to -3 µm. Gain reference was taken at the beginning of the data collection and was applied later in data processing.
Image processing
A total of 7,046 movie stacks were collected. The movie stacks were corrected by gain reference, binned by 2, and corrected for beam-induced motion with MotionCor2. CTF was determined with CTFFIND4 from the motion-corrected sums without doseweighting using a wrapper provided in cryoSPARC2. Dose-weighted sums were used for all the following steps of processing. Particles were autopicked cryoSPARC2.
Particles corresponding to protein molecules were selected from 2D classification.
These particles were then reconstructed ab initio, and then classified with heterogeneous refinement into 3 classes, using two copies of the map generated from the last step plus one junk map as the initial models. The best class was chosen for homogeneous refinement and then non-uniform refinement to obtain a map at 4.1 Å.
The particles were then analyzed with the 3D variability analysis tool and the two extremes of the first eigenvector were used as the basis for further 3D classification.
The final 3D class was refined with non-uniform refinement to a resolution of 3.7 Å. The particle stack was then exported to cisTEM using the scripts in pyEM. After one iteration of local refinement with a mask excluding the detergent micelle, a map was reported at 3.4 Å. The final map after sharpening was used for model building.
Protein model building
Nanobody TI23 structure was generated with rosettaCM using 4mqtB and 5m30F as the template structures. The generated structure and the previously determined PTCH1 structure (6mg8) were docked into the cryo-EM map and refined in phenix.real_space_refine with morphing. The refined model was then edited manually in coot, to add in residues that are now resolved in the new structure, and the small molecules. The constraints for small molecules were generated on the PRODRG server.
The entire structure was then refined in phenix.real_space_refine. 
FACS-based
Gli-dependent luciferase assay
The luciferase assay was performed in Ptch1 -/-MEFs, as previously described ( 
Adeno-associated virus (AAV) production
The backbones of all AAV plasmids were based on pAAV-EF1a-Cre (Addgene, 55636) with poly(A) signal replaced with bGH. AAVs were generated in HEK 293T cells and purified by iodixanol (Optiprep, Sigma; D1556) step gradients as described ( Figure S1 . Selection of nanobody. (a) Yeast cells expressing the initial clones were stained with the antibody used during FACS to ensure that the nanobody binds directly to PTCH1 protein. As summarized in b, Clones 4, 9 and 15 showed strong binding to the antibody and are thus false-positive clones during the selection. (c) Flow chart of the first round of affinity maturation. Nanobody sequences from clone 17, 20 and 23 were mutagenized with error-prone PCR and transformed into yeast. After enriching for PTCH1 binding clones with MACS, the yeast cells are selected in FACS. In the final FACS steps, the cells were first incubated with PTCH1 to allow the nanobodies to bind and after wash, the cells were incubated with the parent nanobody proteins, to compete PTCH1 off the cell surface. FACS plots before and after the competitive chase are shown in d. The cells that retain binding to PTCH1 were selected in FACS. (e) Flow chart of the second round of affinity maturation. The sequence was mutagenized with one-pot mutagenesis and transformed into yeast. Yeast cells expressing the nanobody were selected in FACS with a similar competitive chase. The FACS plots before and after the competition were shown in f. (g) The amino acid sequences of the round 2 affinity maturation library were determined with miSeq and plotted here. The selection enriched for T77N and Y102I variants. 
